Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
TECH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$46.01 - $80.95
Previous CloseN/A
Volume102.39K
Average Volume (3M)2.20M
Market Cap
$7.97B
Enterprise Value$8.25B
Total Cash (Recent Filing)$162.19M
Total Debt (Recent Filing)$444.06M
Price to Earnings (P/E)111.6
Beta0.89
Next Earnings
Nov 04, 2025EPS Estimate
0.43Last Dividend Ex-Date
Aug 18, 2025Dividend Yield0.62%
Share Statistics
EPS (TTM)0.53
Shares Outstanding155,549,590
10 Day Avg. Volume2,156,448
30 Day Avg. Volume2,202,042
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue6.77
Enterprise Value/Gross Profit10.44
Enterprise Value/Ebitda36.99
Forecast
1Y Price Target
$66.00Price Target Upside28.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTECH posted a solid rev/EPS beat with +3% core growth, driven by Protein Sciences.
Product StrengthBio-Techne has a strong consumable mix from high-value reagents in key high-growth end markets like CGT, proteomics, and spatial biology.
Strategic DivestitureThe recent divestiture of ExoDx allows Bio-Techne to free up capital, improve margins, and invest further in its strategic growth areas.
Bears Say
Management GuidanceManagement's preliminary guidance came as a surprise with lower than expected growth projections due to ongoing policy uncertainties.
Market ReactionManagement's messaging on growth outlook led to shares trading down about 8%.
Policy UncertaintyThere is uncertainty due to policy issues such as NIH funding, pharma tariffs, and most-favored nation pricing, affecting short-term growth projections.
Bio-Techne News
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $46.01 and its highest was $80.95 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $7.97B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Nov 04, 2025 which is in 49 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on Aug 06, 2025. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.499 by $0.031.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.62%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.43.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 155,549,590 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.53 in its last earnings report, beating expectations of $0.499. Following the earnings report the stock price went down -8.724%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
Bio-Techne Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.00 (28.76% Upside)
$66.00 (28.76% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 687.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.59%
12-Months-Change
Fundamentals
Return on Equity
3.68%
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corporation (TECH) is a leading global supplier of life science reagents and instruments, primarily serving the pharmaceutical and biotechnology sectors, as well as academic research institutions. The company operates through two main segments: the Protein Platforms segment, which includes a wide array of proteins, antibodies, and reagents used for research and diagnostic applications; and the Diagnostics segment, which offers a range of products for molecular diagnostics and protein analysis. Bio-Techne is known for its innovative solutions that support the development of new therapeutics and diagnostic tests.
TECH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Bio-Techne's earnings call highlighted solid performance in the biopharma sector and strategic moves to enhance profitability, but also underscored challenges in academia and uncertainties in the biotech funding environment. The divestiture of Exosome Diagnostics is expected to improve margins, while potential tariff impacts and NIH funding uncertainties pose risks.View all TECH earnings summariesTECH Net revenue Breakdown
71.35% Protein Sciences
28.39% Diagnostics and Genomics
0.34% Other
TECH Stock 12 Month Forecast
Average Price Target
$66.00
▲(28.76% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Jazz Pharmaceuticals
―
Rhythm Pharmaceuticals
―
Roivant Sciences
―
Ownership Overview
0.25% Insiders
38.73% Mutual Funds
28.85% Other Institutional Investors
8.08% Public Companies and
Individual Investors